Our History
2014
The company was established using IP from collaboration with Kary Mullis, PhD and seed investment.
2015
Laboratories at Discovery Park, Kent were established and the name Centauri Therapeutics adopted. Research using Alphamer® technology started and staff numbers soon grew.
2016
Centauri established a joint venture company, Avvinity Therapeutics, with Horizon Discovery to undertake oncology research using the Alphamer® technology.
2018
Centauri was awarded an Innovate UK grant for £1.3m to undertake anti-infectives research using the Alphamer® technology
2019
Centauri was awarded a CARB-X grant for $1.4m to undertake anti-infectives research using the Alphamer® technology
2022
Centauri secured its Series A investment, moved its laboratory to Alderley Park, Cheshire and was awarded a second CARB-X grant for $2.7m to undertake anti-infectives research using the Alphamer® technology.